Skip to main content

Becton Dickinson's Q1 Revenues Edge up Slightly

NEW YORK (GenomeWeb News) – Becton Dickinson reported today that its first-quarter 2009 revenues rose nearly 2 percent to $1.73 billion from $1.71 billion in the comparable period of 2008.

Revenues for its BD Diagnostics segment increased 3 percent to $540 million from $523 million year over year, including a negative impact of 3 percent from foreign currency translation. Its BD Biosciences segment brought in revenues of $303 million, up 11 percent from revenues of $274 million in the first quarter of 2008, and including a 1 percent benefit from currency translation. Sales for its BD Medical segment dropped 2 percent to $891 million from $909 million, including a 4 percent negative impact from currency translation.

BD's net income climbed 15 percent to $312.1 million, or $1.26 per share, from $271.5 million, or $1.07 per share, year over year.

The firm's R&D spending increased around 7 percent to $97.5 million from $91.5 million, and its SG&A expenses dropped 3 percent to $409.9 million from $421.7 million.

BD said that it expects its full-year 2009 earnings per share to increase around 9 percent to 11 percent over its EPS of $4.46 for fiscal 2008.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.